Overview of Uveal Melanoma, Dr. Prithvi Mruthyunjaya

This presentation is a high level overview of primary tumor treatment, surveillance and adjuvant therapies approaches. It includes commentary on Stanford practices as well as a compare and contrast with other eye centers.
--
Dr. Mruthyunjaya is Associate Professor of Ophthalmology at Stanford University, member of the Vitreoretinal Surgery Service and is the new Director of Ocular Oncology at the Byers Eye Institute. At the Duke Eye Center in Durham, NC, he finished his Ophthalmology residency, Chief Residency, and clinicalresearch fellowships in Vitreoretinal surgery followed by an Ocular Oncology fellowship at the Moorfields Eye Hospital in London, UK. He was on faculty at Duke from 2005-16 where developed an integrated Retina-Ocular Oncology program and was named a tenured Associate Professor of Ophthalmology and Radiation Oncology, Medical Director and Director of Ocular Oncology. Since 2016, he now heads the Stanford Ocular Oncology service and is Director of the vitreoretinal surgical fellowship. Prithvi’s clinical interest lies in the multi-disciplinary, vitreoretinal approach to ocular tumors and simulating conditions. He manages both adult and pediatric ocular cancers with a focus on novel therapeutics, intraocular biopsy, and vision-saving strategies to reduce treatment toxicity. He has authored over 85 papers in peer reviewed journals and his academic contributions were recognized by the American Society of Retina Specialists with a Senior Honor Award. His passion lies in developing collaborative research networks in ocular oncology and training the next generation of vitreoretinal surgeons.

[@almag69]

Excellent expert!!

[@pragyasingh6764]

Is immunotherapy not indicated for ocular melanoma??